Sobi’s Pozdeutinurad Reduces Urate Levels in Phase 3 Trial
Pozdeutinurad reduced urate levels over 12 months in a Phase 3 trial.
Related stories
Ambuja Cements Q2 Net Profit Falls 89.9% to ₹236 Crore
Ambuja Cements reported September-quarter net profit of ₹236 crore, down from ₹2,336 crore a year earlier and below the CNBC-TV18 estimate.
M impact | EQUITY | Oct 29, 2026, 09:33 AM UTC
Asian Paints Q2 Profit Misses Estimates as Costs Rise
Asian Paints reported a second-quarter profit rise that missed estimates, as rising expenses and intensifying competition weighed.
M impact | EQUITY | Oct 29, 2026, 09:18 AM UTC
Sanofi Consumer shares jump 11% after strong Q3 results
Sanofi Consumer Healthcare shares surged as much as 11% in Thursday trading after the company reported strong September-quarter FY27 results. Shares opened at Rs.3,502.20, versus t
M impact | EQUITY | Oct 29, 2026, 09:18 AM UTC
EAAA India Alternatives Sets IPO Offer Price at 1,665 Rupees a Share
EAAA India Alternatives finalised its IPO offer price at 1,665 rupees per share.
L impact | EQUITY | Oct 29, 2026, 09:18 AM UTC
Reservoir Link Energy Insiders Acquire MYR 626,944.50 in Shares
Reservoir Link Energy insiders acquired shares worth MYR 626,944.50.
M impact | EQUITY | Oct 29, 2026, 09:17 AM UTC
Shadowfax Q2 Profit Rises to ₹68 Crore as Revenue Grows 57%
Shadowfax Technologies reported net profit of ₹68 crore for the September quarter, up from ₹13 crore a year earlier. Revenue grew 57% year on year.
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC